Last month, business news outlets were reporting that stock prices for pharmaceutical firms Pfizer and Merck took a tumble after financial analysts downgraded the performance of both firms over concerns about impending patent cliffs or exclusivity issues – although more recent reports paint a mostly promising picture for the companies, thanks to upcoming acquisitions. A pharmaceutical analyst for UBS downgraded Pfizer from buy to neutral, citing the loss of patent protection in the 2025 to 2029 timeframe for several drugs which contributed 30 percent of Pfizer’s total revenue in 2015. For Merck, although patent expiry wasn’t cited in a note from a pharmaceutical analyst from BMO, that analyst dropped Merck’s rating from outperform to market perform based on the expectation that the company’s blockbuster cancer drug Keytruda would face increased competition in the immuno-oncology field during 2019. As of January 30, stock prices for both firms were down by at least a dollar per share from their closing price on January 23. The downgrades for both firms are further proof of the importance of maintaining exclusivity through patent protection to pharmaceutical firms.
The post Merck and Pfizer Downgrades on Patent Cliff Concerns Signal Importance of Patents to Pharma appeared first on IPWatchdog.com | Patents & Patent Law.
- Patent Licensing is a Risky Business: Let the Market Strike the Balance
- mRNA IP and Competitive Landscape: 2021 in Review – Part I, Update on Moderna, BioNTech, and CureVac
- Collaborative Patenting: The Future of IP and Innovation
- Machine Learning Models and the Legal Need for Editability: Surveying the Pitfalls (Part II)
- As Policymakers Say They Want to Rein in Big Tech, Others Seek to Give It Even More Power
- CAFC Nixes District Court Claim Construction in Win for Firearms Patent Owner
- Tips for Litigating Multiple Simultaneous Patent Infringement Investigations at the ITC
- Other Barks & Bites for Friday, January 14: Property Rights Groups Oppose SEP Draft Policy Statement, PTAB POP Issues Ruling on Wire Transfer of IPR Filing Fee, and SCOTUS Denies Appeal in Breach of Royalty Agreement Case
- Senate Judiciary Committee Sends Vidal and Stark Nominations to Senate Floor
- SCOTUS, Vaccine Mandates and Patent Law: God Help Us